The Expression Of Programmed Cell Death 5 And P53 Protein In Mycosis Fungoides Of Different Stages

Objective:To explore the expressions of Programmed Cell Death 5(PDCD5) and P53 in the epidermal keratinocytes and dermal lymphocytes of the skin lesions of patients with granuloma fungoides(mycosis fungoides, MF) in different stages, and to analyse the significance of the human programmed cell death 5 and the epidermal keratinocytes in MF.Materials and Methods:1.24 cases diagnosed by clinic and pathology as mycosis fungoides in the last five years in the department of Dermatology of QiLu Hospital were collected, including 19 cases with the patch stage of MF and 5 cases with the plaque/tumor stage of MF. As normal control,10 normal skin specimens obtained from Plastic Surgery and Minor Operation Room. As positive control,3 specimens of breast cancer were obtained from Pathology Department.2. The expression of PDCD5 and P53 protein in the epidermal keratinocytes and dermal lymphocytes of the skin lesions of patients with MF and normal skins was detected by immunohistochemistry technique.3. By using SPSS13.0 statistical analysis software, the expression of PDCD5 and P53 protein in the epidermal keratinocytes and dermal lymphocytes was tested by rank-sum test of multisample by unitizing engineered; the relevance of the two protein was analysed by Spearman rank correlation, P<0.05 was considered statistically significant.Results:1. The expression of PDCD5 protein in the specimens of the three groups①The overexpression of PDCD5 was localized to the epidermal keratinocytes and dermal lymphocytes of the normal controls, mostly with darkbrown or yellowish-brown, which located in both nuclear and cytoplasm;②In patch stage of MF group, slightly decreased positive cells with buffy in the epidermal keratinocytes and dermal lymphocytes were observed and the positive expression was located in both nuclear and cytoplasm;③In plaque/tumor stage of MF group, significantly decreased positive cells in the epidermal keratinocytes and dermal lymphocytes were observed, even partly absent.④There was no significant difference in the number of PDCD5+ cells between the patch stage of MF and the control group(P>0.05);⑤The PDCD5+ cells in the epidermis and dermis of the plaque/tumor stage of MF were less than those in the control group and the patch stage of MF group(P<0.05).2. The expression of P53 protein in the specimens of the three groups①No expression of P53 protein in the specimens of the normal control group;②The expression of P53 was mainly localized to the epidermal keratinocytes of the specimens of MF, mostly with darkbrown or yellowish-brown, which located only in nuclear;③In epidermal keratinocytes No expression of P53 protein was detected in the epidermal keratinocytes of the control group; P53 protein was positively detected in 36.84%(7/19) patients with patch stage of MF and in 100%(5/5) patients with plaque/tumor stage of MF. And there was statistically significant difference between any two group (,P<0.05);④In dermal lymphocytes There was no expression of P53 protein in the dermis of the control group and the patch stage of MF group, and P53 was positively detected in 20%(1/5) patients with plaque/tumor stage of MF. But there was no significant difference between any two groups (P>0.05).3. correlation analysis between PDCD5 and P53There was no correlation between the expressions of PDCD5 and P53 protein in the epidermis and dennis of different stages of MF (P>0.05).Conclusions:1. With the progression of MF, the expression of PDCD5 in epidermal keratinocytes obviously down regulated even absent, and the expression of P53 in epidermal keratinocytes was increased in that process, which indicates that keratinocyte may play an important role in the tumorigenesis of MF, but the mechanism needs further investigation.2. With the progression of MF, the expression of PDCD5 in dermal lymphocytes obviously down regulated even absent, which indicates that PDCD5 may be correlated with the tumorigenesis of MF. It may contribute to inhibit proliferation of lymphocyte by up-regulating the expression of PDCD5, and PDCD5 is expected to become a new target for treatment of MF.3. No correlation was observed between the expression of PDCD5 and P53, which suggests that the two factors may promote apoptosis in different pathways, or perhaps there was limitation because of the little specimens in our research.